HFA Premium Access

What proportion of patients with HFrEF might be candidates for Sacubitril-Valsartan?

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Congress Presentation

About the speaker

Doctor Tim O connor

Galway university hospital, Dublin (Ireland)
1 presentation
0 follower

6 more presentations in this session

Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin


Heart failure patients with reduced left ventricular ejection fraction, who reached 100% target dose of beta-blockers in randomized and observational studies

Speaker: Mrs M. Oyanguren Artola (Bilbao, ES)


Metabolic response to exercise training in heart failure with preserved ejection fraction

Speaker: Doctor M. Bahls (Greifswald, DE)


Adherence to ESC guidelines after hospital admission for heart failure in 22500 Dutch patients: 2001-2015

Speaker: Mrs W. Kruik-Kolloffel (Almelo, NL)


Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure

Speaker: Doctor S. Zheng (London, GB)


Access the full session

Moderated Poster session 3 - Novel treatment

Speakers: Doctor T. O connor, Mrs M. Oyanguren Artola, Doctor M. Bahls, Mrs W. Kruik-Kolloffel, Doctor S. Zheng

About the event


Heart Failure 2018

26 May - 29 May 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb